The aim of this systematic review is to compare home and office desensitizers containing bioactive glass with control groups in randomized controlled trials (RCT) conducted between 2018 and 2022. According to PRISMA guidelines, three electronic databases (Scopus, PubMed, and Cochrane Library) were searched for published scientific articles in October 2022. RCT with adult participants with dentin hypersensitivity (DH) diagnosed by evaporative, mechanical, or thermal stimulation, with a follow-up period and quantified pain assessment were included in the study. Studies that reported DH due to tooth restoration, crown preparation, bleaching, or periodontal surgery or used bioactive glass-ceramics were excluded. The quality of the studies was assessed using version 2 of the Cochrane Risk-of-Bias Tool for randomized studies (RoB 2 tool). Articles that were duplicative or unrelated to this study were excluded. Nine articles were selected for full-text evaluation, whereas two articles were rejected. The remaining seven reports were included in this review. The calcium sodium phosphosilicate group (CSPS) was not significantly different from the positive control groups. Compared with the control groups, fluoro calcium phosphosilicate (FCPS) may be the most effective long-term treatment option. In terms of DH symptom reduction, the FCPS group performed better than the CSPS group. CSPS at a concentration of 5–15% and FCPS at a concentration of 5% are effective in treating DH in adult participants.

Background and Objectives: Contrast-enhanced mammography (CEM) provides both morphological and functional information and may reflect breast cancer biology similarly to Magnetic Resonance Imaging (MRI). Materials and Methods: This single-center retrospective study included 399 women with Breast Imaging Reporting and Data System (BI-RADS) category 0 screening mammograms who subsequently underwent CEM. A total of 76 malignant lesions (68 invasive cancers, 8 ductal carcinoma in situ (DCIS)) with complete imaging and pathology data were analyzed. Invasive cancers were classified into luminal A, luminal B, luminal B/Human Epidermal Growth Factor Receptor 2 (HER2)-positive, HER2-enriched, and triple-negative, and grouped as luminal (Group 1) versus HER2-positive/triple-negative (Group 2). Results: Luminal subtypes predominated (47 of 68, 69%), while 21 of 68 (31%) were HER2-positive or triple-negative. Most cancers appeared as masses with spiculated margins and heterogeneous enhancement. Significant differences were observed in mass shape (p = 0.03) and internal enhancement (p = 0.01). Luminal tumors were more often irregular and spiculated with heterogeneous enhancement, whereas the HER2-positive/triple-negative tumors more frequently appeared round with rim or homogeneous enhancement. Deep learning-derived malignancy scores (iCAD ProFound AI^®) demonstrated good diagnostic performance (area under the curve (AUC) = 0.744, 95% confidence interval (CI) 0.654–0.821, p < 0.001). The median AI score was significantly higher in malignant compared with benign lesions (70% [interquartile range (IQR) 47–93] vs. 38% [IQR 25–61]; Mann–Whitney U test, p < 0.001). Among malignant lesions, iCAD scores varied across molecular subtypes, with higher median values observed in Group 1 versus Group 2 (87% vs. 55%), although the difference was not statistically significant (Mann–Whitney U test, p = 0.35). Conclusions: CEM features mirrored subtype-specific phenotypes previously described with MRI, supporting its role as a practical tool for enhanced tumor characterization. Although certain imaging and AI-derived parameters differed descriptively across subtypes, no statistically significant differences were observed. As deep-learning models continue to evolve, the integration of AI-enhanced CEM into clinical workflows holds strong potential to improve lesion characterization and risk stratification in personalized breast cancer diagnostics.

Synthetic calcium phosphates have been tested in randomised trials of sinus augmentation and ridge preservation but rarely in ridge augmentation. To our knowledge, the augmented volume of biphasic calcium phosphate (BCP) mixed with autogenous bone has not been measured clinically in non-contained ridge defects. We grafted four such maxillary defects with BCP (RESORBA Synthetic Bone, hydroxyapatite/β-tricalcium phosphate 60/40; S1, S2) or porcine xenogeneic mineral (RESORBA Xenogenic Bone Graft; X1, X2), each mixed 50:50 with scraper-harvested autogenous chips, under a native collagen membrane (PARASORB RESODONT Forte). Cone-beam computed tomography volumetry gave the net radiodense volume (new bone and residual graft) in a fixed 10 × 10 mm window, with measurement envelopes over analysis choices. All four sites healed uneventfully and received implants, with the graft (S1, X1) or at re-entry (S2, X2), S2 with 2 mm of buccal hard tissue despite loose particles outside the contour. All were uneventful for 13–65 months after grafting, apart from one resolved sinus tract in X1. Volumes (mm³, envelopes in brackets) were 99.7 (91.8–112.3) in S1 and 137.0 (127.6–150.8) in X1, their envelopes overlapping before the post hoc changes, and 95.4 (82.3–99.5) in S2 and 267.1 (261.4–272.3) in X2, apart before and after them. As each volume difference is also one between patients and sites, none is attributed to the substitute.